Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- The team shrank two years in a row.
Revenue
€ 0
▼ 100% vs 2024
Profit
Caution€ -2.3 million
▼ 13% vs 2024
Debts
Normal€ 8.8 million
▼ 6% vs 2024
EXO Biologics from Liège, company number BE0732982379, closed financial year 2025 with a result of € -2.3 million after tax. For that financial year EXO Biologics recorded revenue of € 0 and equity of € 2.9 million. Compared with financial year 2024, the result moved from € -2.1 million to € -2.3 million. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
What happened at EXO Biologics?
What happened at EXO Biologics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Stijn Van Rompay stepped down as director. NBB
- NOSHAQ PARTNERS SRL stepped down as director. NBB
- Jean Michel Foidart stepped down as director. NBB
- Margarite Limited S. Etr. stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.3 million. Source: NBB ↗
- Stijn Van Rompay became a director. NBB
- NOSHAQ PARTNERS SRL became a director. NBB
- Jean Michel Foidart became a director. NBB
In short
From € 2.5 million loss in 2021 to € 2.3 million loss in 2025.
On average € 73,100 of value added per employee in 2025.
A new publication or filing at EXO Biologics? We notify you, reason included.
Follow EXO BiologicsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of ExoXpert SRL itself.
Directors
According to the 2025 annual accounts
Stijn Van Rompay
Managing director
Also active at: J.D.P. Consult, SVR INVEST, SVR Management +6 more
since 2023 · until 2029
Director · represented by Eric Brandt
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE +174 more
since 2023 · until 2029
since 2023 · until 2029
Director · represented by Dalton Colin
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3 box 2
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 23 companies are registered at this address.
Hyloris Developments
€ 5.1 million revenue · 2025
ONCORADIOMICS same network
€ 2.4 million gross margin · 2025
DERMAX same network
€ 1.6 million revenue · 2025
Hyloris same network
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
+18 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
Website info
Features
Security
Details
- Company number
- 0732.982.379
- VAT number
- BE 0732.982.379
- Registered office
- Boulevard de Patience et Beaujonc 3 bus 2, 4000 Liège
- Names & denominations
- EXO Biologics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 August 2019
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- exobiologics.be
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van overige farmaceutische producten